NAT2 Antibody, Biotin conjugated

說明書

中文名稱：

NAT2兔多克隆抗體, Biotin偶聯(lián)
貨號：

CSB-PA015471LD01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) NAT2 Polyclonal antibody
Uniprot No.：

P11245
基因名：

NAT2
別名：

AAC2 antibody; ARY2_HUMAN antibody; Arylamide acetylase 2 (N-acetyltransferase 2, isoniazid inactivation) antibody; Arylamide acetylase 2 antibody; Arylamine N-acetyltransferase 2 antibody; HGNC:7646 antibody; N-acetyltransferase 2 (arylamine N-acetyltransferase) antibody; N-acetyltransferase type 2 antibody; NAT-2 antibody; NAT2 antibody; PNAT antibody; Polymorphic arylamine N-acetyltransferase antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Arylamine N-acetyltransferase 2 protein (1-290AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Biotin
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
基因功能參考文獻(xiàn)：
1. NAT2 genetic polymorphism predisposes children with connective tissue dysplasia to adhesion ileus. PMID: 30479108
2. It is concluded that the frequency of slow encoding NAT2 haplotype was high among Jordanian volunteers, which may have effects on drug responses and susceptibility to some diseases, such as cancers. PMID: 29173142
3. We report a high prevalence of NAT 2 slow acetylators in Ethiopians and a conditional NAT2 genotype-phenotype country-of-residence-based discordance implicating a partial phenotype conversion and metabolic adaptation. Gene-environment interactions regulate NAT2 phenotype. PMID: 29589062
4. NAT2 genetic variants are associated with urinary bladder cancer risk. PMID: 28577040
5. Letter: in bladder cancer ultra-slow acetylators with the NAT2*6A/*6A genotype have a higher recurrence risk and a shorter recurrence-free time, especially among smokers. PMID: 28040354
6. NAT2 polymorphism is not associated with passive smoking associated breast cancer risk. PMID: 29071579
7. NAT2 role in the metabolic detoxification of heterocyclic aromatic amines PMID: 28160022
8. hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies PMID: 29018032
9. Studied the association between N-acetyl transferase 2 (NAT2)genetic polymorphisms, environmental factors and risk factors in colon or rectal cancer. PMID: 27883249
10. prevalence impaired glucose tolerance higher in obese children carrying the A803 allele PMID: 27481583
11. There were significant differences in NAT2(rs1799929, rs1799930) genotype or allele frequencies between the infertile and fertile groups and synergy effects of GSTP1 and NAT2 polymorphisms might lead to significant increase of infertility risk. PMID: 29505746
12. The increased risk of prostate cancer was observed among individuals with the NAT2 slow acetylator phenotype PMID: 29165164
13. Genotyping of TB patients from south India for NAT2 gene polymorphism revealed that 58 per cent of the study population comprised slow acetylators. Two-hour INH concentrations differed significantly among the three genotypes. PMID: 28574024
14. Slow NAT2 acetylators demonstrated a significant association with risk of anti-tuberculosis drug-induced liver injury in Thai patients. PMID: 27725049
15. The present study demonstrated no association between NAT2 genotype and drug-induced hepatotoxicity in the north Indian patients with tuberculosis. PMID: 28474630
16. SNP-inferred slow acetylation statuses were significantly associated with an approximately 50% decreased risk of bladder cancer PMID: 27223070
17. CYP3A4 expression and N-acetyl transferase 2 acetylator phenotype can better identify the patients with higher risk of adverse reactions and can facilitate the improvement of personalized clonazepam therapy and withdrawal regimen. PMID: 27639091
18. NAT2 genotypes are associated with N-acetylation phenotype variation. PMID: 28653770
19. NAT2 acetylator genotype has an important role in 4, 4'-methylene bis (2-chloroaniline) metabolism and suggest that risk assessments related to 4, 4'-methylene bis (2-chloroaniline) exposures consider accounting for NAT2 acetylator phenotype in the analysis PMID: 29180287
20. Review/Meta-analysis: NAT2 slow acetylation genotype is associated with an increased bladder cancer risk in Chinese individuals. PMID: 28182356
21. six selected NAT2 exonic single nucleotide polymorphisms were genotyped in an independent case-control sample of a Northern Chinese Han population to verify the possible association between NAT2 and schizophrenia. Three (rs1801280T/341C, rs1799930/G590A, and rs1208/A803G) of the six single nucleotide polymorphisms showed significant allele frequency differences between the case and the control groups. PMID: 28187106
22. Our findings suggested that NAT2 gene polymorphism rs1799931 was associated with decreased risk of acute myeloid leukemia and was likely to be a protective factor against acute myeloid leukemia development. PMID: 29049179
23. Study reestablished the association between NAT2 SA and isoniazid-induced liver injury in a Singaporean population and demonstrated its clinical validity in prediction of isoniazid-induced liver injury. PMID: 29036176
24. In non-syndromic cleft lip with or without cleft palate, we found a significant association between the EGF61 (rs4444903) and NSCL/P (P = .01) genes. Conversely, NAT2 (rs1799929) was not significantly different between the cases and the control group PMID: 28906376
25. 182 Hungarian bladder cancer cases and 78 cancer-free controls were investigated. It was not possible to establish a particular impact of NAT2*6A and *7B genotypes (15 cases, 8%, 5 controls, 7%). GSTT1 exerted no marked influence on bladder cancer (negative 21% cases vs. 22% controls). The portion of GSTM1 negative bladder cancer patients was increased (63% cases vs. 54% controls). PMID: 28696897
26. Various antitubercular isoniazid dosing regimens have been proposed for NAT2-specific immunocompetent and immune-deficient patient populations. PMID: 27480867
27. Data suggest that metabolism (and possibly pharmacokinetics) of hypnotic nitrazepam involves liver enzymes AOX1 (aldehyde oxidase 1), NAT2 (N-acetyltransferase 2), AADAC (arylacetamide deacetylase), and CYP3A4 (cytochrome P450 3A4). PMID: 28606603
28. The multicolor melting curve assay described in our study is very promising for the efficient determination of NAT2 genotype, and can facilitate the personalized dosing of isoniazid PMID: 27377479
29. No significant differences in the acetylator NAT2 haplotype and phenotype distributions were found between Native American populations practicing farming and/or herding and those practicing hunting and gathering. PMID: 26503810
30. In any patient who may receive INH and happens to be NAT2 slow acetylator type, NAT2 genotype by covert action may influence the clinical response of above drugs. PMID: 27487996
31. Homozygous mutant allele of NAT2 gene at 481site may act as a predisposing factor for phenytoin intoxication among tuberculous meningitis or tuberculoma patients having seizures. PMID: 27488001
32. In the present study, we report that the most common NAT2 haplotype in the Korean population (TACGAGG; frequency = 47.6%) is associated with a low expression level of NAT2. We failed to find a significant relationship between rs4646241 and enzyme expression level. Haplotypes of Caucasian and African populations were markedly different from those of the Korean population. PMID: 27853051
33. We genotyped four selected variants of the NAT2 gene (NAT2*5, NAT2*6, NAT2*7, and NAT2*14) by Sanger sequencing. The majority of patients had NAT2 genotypes previously described as slow acetylators including NAT2*5/*5, NAT2*5/*6, NAT2*6/*6, and NAT2*6/*14 (78%) and none were genotyped as rapid acetylators. Controls were slow, intermediate, and rapid acetylators with frequencies of 72.39%, 21.48%, and 6.13%, respectively PMID: 27541622
34. this study confirms the significance of the association between slow-acetylator NAT2 variants and susceptibility to AT-DILI in an Indonesian population. PMID: 26911349
35. NAT2 gene variants were associated with antituberculosis drug-induced hepatotoxicity. PMID: 27104815
36. Single nucleotide polymorphism is associated with different N-acetyltransferase-2 acetylator phenotypes in wordwide population groups. PMID: 27136043
37. Association of NAT2 single nucleotide polymorphism and breast cancer risk with smoking in Japanese women PMID: 27068825
38. NAT2 slow acetylators have a higher risk of noncardiac gastric adenocarcinoma than intermediate and rapid acetylators have in a Taiwanese population. PMID: 26617241
39. NAT2 single nucleotide polymorphism associated with the risk bladder cancer development and interacts with smoking. PMID: 27495060
40. NAT2 gene polymorphisms (rs1041983 C/T, rs1801280 T/C, and rs1799930 G/A) in association with long-period active smoking could be the possible individual risk-predicting factors for breast cancer development in the population of Slovak women PMID: 26700672
41. Data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with Parkinson's diease risk, except in Asian populations PMID: 27216438
42. Results show that NAT2 polymorphism was associated with increased risk of coronary heart disease in Chinese population. PMID: 26985933
43. NAT2 acetylation status and its single nucleotide polymorphisms in the Greenlandic population, including Inuit and European ancestry PMID: 25794903
44. Results showed that the NAT2 slow acetylation phenotypes are significantly associated with an increased risk of bladder cancer. PMID: 26585839
45. NAT2 slow acetylation state was associated with bladder cancer risk, and was shown to modestly increase the risk of bladder cancer. PMID: 26681036
46. the NAT2 slow acetylation genotypes might increase the susceptibility to pancreatic cancer in Europe but that these have no significant effects in the United States and multi-center populations. PMID: 26681215
47. Findings suggest that variations in the NAT2 gene and their interactions contribute to occupational diisocyanate asthma susceptibility. PMID: 26641831
48. The results suggest that NAT2 is related to cognitive processes dealing with distraction and attentional control in the auditory modality; ultra-slow acetylation status was associated with reduced higher cognitive functions PMID: 26615528
49. Individuals with NAT2 slow acetylators may have increased risk of antituberculosis drug-induced liver injury when standard dose of isoniazid was used. [META-ANALYSIS] PMID: 26616266
50. Findings support a role for NAT2 in modifying the association between red meat consumption and colorectal cancer in Japanese and African Americans. PMID: 26683305
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm.
蛋白家族：

Arylamine N-acetyltransferase family
數(shù)據(jù)庫鏈接：

HGNC: 7646

OMIM: 243400

KEGG: hsa:10

STRING: 9606.ENSP00000286479

UniGene: Hs.2

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human